Literature DB >> 35064379

Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma.

Xiang-Ping Yang1, Liu Huang2, Junmei Weng3, Lian Chen4, Huicheng Liu3.   

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common hematological malignancy in adults. Ferroptosis is an iron-dependent programmed cell death caused by lipid peroxidation. However, the potential functions of ferroptosis in the DLBCL prognosis, immune infiltration, and drug resistance remain unknown. Data of DLBCL patients were downloaded from public GEO databases and TCGA cohort. R software was used for analysis. Ferroptosis-related risk score model was constructed using LASSO Cox regression analysis. The prognosis of the model and its association with immune cells infiltration and ibrutinib-resistance were studied by single-sample gene set enrichment analysis (ssGSEA) and correlation analysis. Ferroptosis-related risk score model was constructed with 11 ferroptosis-related genes. DLBCL patients can be divided into high- or low-risk groups with this model. High-risk patients had significant shorter survival (p < 0.001). The area under curve at 3-year was 0.779. Functional enrichment analysis was mainly associated with the immune response. High score patients were positively correlated with immunosuppressive cell infiltration, including macrophages and regulatory T cells, and immunoevasion checkpoints, such as CTLA4, PD-L1, LAG-3, and TIM-3. We also found that tumors with high risk would resist to ibrutinib treatment and uncovered that acetaminophen, as a ferroptosis inducer, inhibited the defined high-risk gene expression in the ibrutinib-resistant DLBCL cell lines. Ferroptosis-related risk score model can predict the overall survival (OS) of DLBCL patients and ibrutinib resistance of ABC-DLBCL cells, which was associated with immunosuppression status within the tumor microenvironment.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  DLBCL; Ferroptosis; Ibrutinib resistance; Immune infiltration.

Mesh:

Substances:

Year:  2022        PMID: 35064379     DOI: 10.1007/s10753-021-01609-6

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  40 in total

1.  Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  H Tilly; M Gomes da Silva; U Vitolo; A Jack; M Meignan; A Lopez-Guillermo; J Walewski; M André; P W Johnson; M Pfreundschuh; M Ladetto
Journal:  Ann Oncol       Date:  2015-09       Impact factor: 32.976

2.  Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

Authors:  Constantine S Tam; Judith Trotman; Stephen Opat; Jan A Burger; Gavin Cull; David Gottlieb; Rosemary Harrup; Patrick B Johnston; Paula Marlton; Javier Munoz; John F Seymour; David Simpson; Alessandra Tedeschi; Rebecca Elstrom; Yiling Yu; Zhiyu Tang; Lynn Han; Jane Huang; William Novotny; Lai Wang; Andrew W Roberts
Journal:  Blood       Date:  2019-07-24       Impact factor: 22.113

Review 3.  Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.

Authors:  R Andrew Harkins; Andres Chang; Sharvil P Patel; Michelle J Lee; Jordan S Goldstein; Selin Merdan; Christopher R Flowers; Jean L Koff
Journal:  Expert Rev Hematol       Date:  2019-09-12       Impact factor: 2.929

4.  Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Authors:  Zijun Y Xu-Monette; Ling Li; John C Byrd; Kausar J Jabbar; Ganiraju C Manyam; Charlotte Maria de Winde; Michiel van den Brand; Alexandar Tzankov; Carlo Visco; Jing Wang; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Ben M Parsons; Jane N Winter; Michael Wang; Frederick B Hagemeister; Miguel A Piris; J Han van Krieken; L Jeffrey Medeiros; Yong Li; Annemiek B van Spriel; Ken H Young
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

5.  Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Authors:  Anas Younes; Laurie H Sehn; Peter Johnson; Pier Luigi Zinzani; Xiaonan Hong; Jun Zhu; Caterina Patti; David Belada; Olga Samoilova; Cheolwon Suh; Sirpa Leppä; Shinya Rai; Mehmet Turgut; Wojciech Jurczak; Matthew C Cheung; Ronit Gurion; Su-Peng Yeh; Andres Lopez-Hernandez; Ulrich Dührsen; Catherine Thieblemont; Carlos Sergio Chiattone; Sriram Balasubramanian; Jodi Carey; Grace Liu; S Martin Shreeve; Steven Sun; Sen Hong Zhuang; Jessica Vermeulen; Louis M Staudt; Wyndham Wilson
Journal:  J Clin Oncol       Date:  2019-03-22       Impact factor: 44.544

6.  A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.

Authors:  George W Wright; Da Wei Huang; James D Phelan; Zana A Coulibaly; Sandrine Roulland; Ryan M Young; James Q Wang; Roland Schmitz; Ryan D Morin; Jeffrey Tang; Aixiang Jiang; Aleksander Bagaev; Olga Plotnikova; Nikita Kotlov; Calvin A Johnson; Wyndham H Wilson; David W Scott; Louis M Staudt
Journal:  Cancer Cell       Date:  2020-04-13       Impact factor: 31.743

Review 7.  Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Nat Rev Clin Oncol       Date:  2013-11-12       Impact factor: 66.675

8.  Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.

Authors:  A Bari; L Marcheselli; S Sacchi; R Marcheselli; S Pozzi; P Ferri; E Balleari; P Musto; S Neri; M A Aloe Spiriti; M C Cox
Journal:  Ann Oncol       Date:  2009-11-17       Impact factor: 32.976

9.  International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.

Authors:  Amy S Ruppert; Jesse G Dixon; Gilles Salles; Anna Wall; David Cunningham; Viola Poeschel; Corinne Haioun; Herve Tilly; Herve Ghesquieres; Marita Ziepert; Jocelyne Flament; Christopher Flowers; Qian Shi; Norbert Schmitz
Journal:  Blood       Date:  2020-06-04       Impact factor: 22.113

10.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

View more
  1 in total

1.  Levistilide a Induces Ferroptosis by Activating the Nrf2/HO-1 Signaling Pathway in Breast Cancer Cells.

Authors:  Shangwen Jing; Yantong Lu; Jing Zhang; Yan Ren; Yousheng Mo; Dongdong Liu; Lining Duan; Zhongyu Yuan; Changjun Wang; Qi Wang
Journal:  Drug Des Devel Ther       Date:  2022-09-07       Impact factor: 4.319

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.